Published in Am J Med on June 07, 1985
Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut (2003) 1.63
Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother (2006) 0.98
Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother (1993) 0.95
Imipenem therapy of experimental Staphylococcus epidermidis endocarditis. Antimicrob Agents Chemother (1986) 0.92
Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother (1997) 0.89
Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel) (2010) 0.88
Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1988) 0.85
Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrob Agents Chemother (1992) 0.85
Pharmacokinetics and transplacental passage of imipenem during pregnancy. Antimicrob Agents Chemother (1992) 0.84
Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. Antimicrob Agents Chemother (1999) 0.82
Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. Antimicrob Agents Chemother (1991) 0.75
Intravenous treatment of experimental Staphylococcus aureus endophthalmitis: imipenem versus the combination of ceftazidime and amikacin. Graefes Arch Clin Exp Ophthalmol (2003) 0.75
[Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections]. Infection (1986) 0.75
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother (1993) 4.76
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs (1999) 2.83
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother (1994) 2.46
Gentamicin: in vitro studies. J Infect Dis (1969) 2.46
Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 2.44
Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 2.43
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 2.24
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1974) 2.08
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 2.03
Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother (1984) 1.98
Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.97
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother (1999) 1.90
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Laboratory and clinical experience with cephalexin. Antimicrob Agents Chemother (Bethesda) (1968) 1.76
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother (2011) 1.75
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother (1998) 1.73
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis (2007) 1.70
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother (2005) 1.69
Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis (1970) 1.68
BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1975) 1.61
Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med (1981) 1.53
The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis (1984) 1.48
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother (2011) 1.46
Fluoroquinolone pharmacodynamics. Clin Infect Dis (2001) 1.45
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis (1995) 1.43
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2011) 1.35
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison. Rev Infect Dis (1984) 1.33
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2007) 1.33
The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity. Ann Intern Med (1974) 1.33
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother (1984) 1.31
An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother (1986) 1.31
Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med (1979) 1.31
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet (1982) 1.28
Laboratory and clinical studies of carbenicillin against gram-negative bacilli. Antimicrob Agents Chemother (Bethesda) (1968) 1.27
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother (2010) 1.27
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother (1993) 1.26
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther (1990) 1.25
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother (2005) 1.24
Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.23
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother (1998) 1.23
Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1987) 1.22
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect (2009) 1.22
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1993) 1.21
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother (1999) 1.21
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1995) 1.20
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother (1986) 1.18
Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med (1970) 1.17
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother (1987) 1.17
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother (2009) 1.16
Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med (1986) 1.15
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2008) 1.14
Development of staphylococci cross-resistant to cephalexin and methicillin. Antimicrob Agents Chemother (Bethesda) (1968) 1.13
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother (1998) 1.12
Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med (1982) 1.12
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother (1987) 1.12
Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother (2009) 1.10
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol (1984) 1.08
Activity of novobiocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother (1985) 1.08
Ticarcillin in combination with cephalothin or gentamicin as empiric antibiotic therapy in granulocytopenic cancer patients. Antimicrob Agents Chemother (1976) 1.08
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother (2009) 1.07
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother (1999) 1.06
Gentamicin and ticarcillin serum levels. JAMA (1979) 1.06
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother (2009) 1.05
Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis (2001) 1.05
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J (2009) 1.03
Latex agglutination inhibition card test for gentamicin assay: clinical evaluation and comparison with radioimmunoassay and bioassay. Antimicrob Agents Chemother (1981) 1.03
Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother (1981) 1.03
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother (1987) 1.03
Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother (2003) 1.03
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob Agents Chemother (1998) 1.03
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother (2010) 1.03
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents. Antimicrob Agents Chemother (1985) 1.02
Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin (2011) 1.02
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother (2006) 1.01
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother (1994) 1.00
Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther (1985) 1.00
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother (2012) 1.00
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother (1989) 1.00
Methicillin-resistant Staphylococcus aureus infections: it's time to get tough. Infect Control (1987) 1.00